Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and targets for identifying compounds for regulating rhinovirus infection

A technology for compounds and rhinoviruses, applied in the fields of compound screening, antiviral agents, biomaterial analysis, etc., can solve problems such as lack of screening target screening methods

Inactive Publication Date: 2010-01-06
THE PROCTER & GAMBLE COMPANY
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, one problem associated with identifying compounds for the treatment of colds is the lack of good screening targets and good screening methods for identifying such compounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and targets for identifying compounds for regulating rhinovirus infection
  • Methods and targets for identifying compounds for regulating rhinovirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment A

[0152] The in vitro cell line of BEAS-2B cells can be infected with rhinovirus RV-16. The cells are then exposed to a variety of compounds and extracts, and then tested and analyzed for the content of respiratory biomarker proteins. By monitoring the content of respiratory biomarker protein after exposing infected cells to the extract and compound and comparing it with the content of respiratory biomarker protein in infected cells not exposed to the extract and compound, the extract and compound can be identified as A substance that regulates respiratory biomarker proteins.

[0153] In the described embodiment, the test component is the herb Andrographis paniculata extract or its main component andrographolide. The content of andrographolide in the test component is 5μM. The respiratory biomarker protein is IP-10 (CXCL10), a chemotactic agent.

[0154] Test ingredients

(5μM andrographolide content)

IP-10(CXCL10)

pg / mL

Control

61.99

Andrographolide

18.07

And...

Embodiment B

[0159] The efficacy of the test compound during rhinovirus infection that naturally induces a cold can be evaluated by monitoring the content of respiratory protein biomarkers. A nasal wash was collected from subjects who showed the initial symptoms of a cold. The subject was then treated and samples of nasal wash were collected over the next few days.

[0160] The therapeutic agent consisted of standardized andrographis extract containing 20 mg of total andrographolide, 28.8 mg of Acanthopanax senticosus extract and 650 mg of curcumin (curcumin extract). This composition is taken three times a day. The respiratory biomarker protein is IP-10 (CXCL10), a chemotactic agent. In the few days after treatment, the content of respiratory biomarker protein was detected and analyzed, and the baseline value before treatment was used for statistical correction.

[0161] Test ingredients

IP-10(CXCL10)

pg / mL

Control

8183

Andrographis, Acanthopanax senticosus, and curcumin com...

Embodiment C

[0166] The efficacy of the test compound during rhinovirus infection that naturally induces a cold can be evaluated by monitoring the content of respiratory protein biomarkers. A nasal wash was collected from subjects who showed the initial symptoms of a cold. The subject was then treated and samples of nasal wash were collected over the next few days.

[0167] The therapeutic agent consisted of 400 mg ibuprofen and 4 mg chlorpheniramine maleate. The composition is taken three times a day. The respiratory biomarker protein is MCP1 (CCL2), a chemotactic agent. In the few days after treatment, the content of respiratory biomarker protein was detected and analyzed, and the baseline value before treatment was used for statistical correction.

[0168] Test ingredients

MCP1(CCL2)

pg / mL

Control

271

Combination of ibuprofen and chlorpheniramine maleate.

163

[0169] Ibuprofen was obtained from Wyeth Consumer Healthcare, Wilmington DE.

[0170] Chlorpheniramine maleate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods for identifying genes, expression regulators, receptors, protein product receptors, and proteins that may regulate rhinovirus infections. The genes identified may be used as markers for disease onset and progression and to measure efficacy of a therapeutic. The present invention also provides methods to screen agents that are capable of regulating rhinovirus infection. The present invention also provides methods of identifying therapeutic compounds that may treat various disorders by regulating the expression and activity of genes, expression regulators, receptors, protein product receptors, and proteins identified.

Description

Invention field [0001] The present invention relates to methods for identifying target genes, proteins, expression regulators, receptors, protein product receptors, and compounds for regulating, diagnosing, and monitoring rhinovirus infections. Background of the invention [0002] Cold symptoms are mainly caused by 200 different viruses, of which about 30% to 50% of colds are caused by rhinovirus. They are also the most common pathogens that cause acute attacks of asthma and chronic obstructive pulmonary disease (COPD). However, the mechanism of rhinovirus triggering or exacerbating airway diseases has not been fully elucidated. [0003] Cold infections are so common that it is estimated that adults may catch 2 to 3 colds a year, and children may catch 5 to 7 colds a year. In the United States, 50% of medical visits are related to respiratory diseases. Colds cause 50% of short-term absences from work and school. The average duration of a cold is 7 to 10 days. Effective treatme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/569
CPCG01N2500/00G01N33/56983G01N2333/095A61P31/12
Inventor 玛丽·林恩·江普杰弗里·沃伦·克莱默贝格尼亚·Y·霍埃米·安·瓦兰斯基辛西娅·E·弗朗西斯
Owner THE PROCTER & GAMBLE COMPANY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com